Allspring Global Investments Holdings LLC Has $330.23 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,808,002 shares of the medical research company's stock after acquiring an additional 47,221 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 3.54% of Charles River Laboratories International worth $330,231,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in CRL. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International in the third quarter valued at $32,000. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. lifted its stake in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $56,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

CRL stock traded down $1.10 during mid-day trading on Friday, hitting $152.07. The stock had a trading volume of 841,129 shares, compared to its average volume of 1,002,698. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The firm has a market capitalization of $7.78 billion, a P/E ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37. The firm has a fifty day simple moving average of $176.43 and a 200 day simple moving average of $191.11.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CRL. TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a research report on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).